Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272–87. https://doi.org/10.1093/cvr/cvac013.

Article  CAS  Google Scholar 

Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012–2015. Eur J Heart Fail. 2019;21:1329–37.

Article  PubMed  Google Scholar 

Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the china heart failure (China-HF) registry. J Card Fail. 2017;23:868–75.

Article  PubMed  Google Scholar 

Moayedi Y, Fan CPS, Cherikh WS, et al. Survival outcomes after heart transplantation: does recipient sex matter? Circ Heart Fail. 2019;12:e006218.

Article  PubMed  Google Scholar 

Tamayo C, Huertas J, Sanmartin D, et al. Cost-effectiveness of tacrolimus compared with cyclosporine for immunosuppression therapy in patients who underwent heart transplant in Colombia. Value Health Reg Issues. 2023;38:61–8.

Article  PubMed  Google Scholar 

Sun Y-F, Wang Z-W, Zhang J, et al. Current status of and opinions on heart transplantation in China. Curr Med Sci. 2021;41:841–6.

Article  PubMed  PubMed Central  Google Scholar 

Huang J, Liao Z. Chinese Criteria for Immunosuppressive Therapy and Rejection of Heart Transplantation (2019 edition). Chin J Transpl. 2019;13:15–20.

Google Scholar 

Eisen HJ. Pharmacology of Immunosuppression. Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-05118-0. Accessed 18 Dec 2022

Nelson J, Alvey N, Bowman L, et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American college of clinical pharmacy, American society of transplantation, and the international society for heart and lung transplantation. Pharmacother J Hum Pharmacol Drug Ther. 2022;42:599–633.

Article  CAS  Google Scholar 

Saber-Moghaddam N, Nomani H, Sahebkar A, et al. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation. Int Immunopharmacol. 2019;69:150–8.

Article  PubMed  CAS  Google Scholar 

Zieliński T. Mammalian target of rapamycin inhibitors in heart transplantation what we know and do not know? Int J Cardiol. 2018;265:79–80.

Article  PubMed  Google Scholar 

Asleh R, Briasoulis A, Kremers W, et al. Long-term sirolimus for primary immunosuppression in heart transplant recipients. J Am Coll Cardiol. 2018;71:636–50.

Article  PubMed  CAS  Google Scholar 

Tedesco-Silva H, Saliba F, Barten MJ, et al. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. Transplant Rev. 2022;36:100655.

Article  Google Scholar 

Zuckermann A, Keogh A, Crespo-Leiro MG, et al. Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg. 2012;12:2487–97.

Article  CAS  Google Scholar 

Announcement of the Chinese Pharmaceutical Society on the release of group Standards for the “Chinese Pharmacoeconomics Evaluation Guidelines 2020”: Chinese Pharmaceutical Society. https://www.cpa.org.cn/index.php?do=info&cid=75553. Accessed 1 Aug 2023.

Long EF, Swain GW, Mangi AA. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail. 2014;7:470–8.

Article  PubMed  CAS  Google Scholar 

China Census Yearbook -2020. Available from: http://www.stats.gov.cn/sj/pcsj/rkpc/7rp/indexch.htm. Accessed 13 Nov 2023.

Ng AK-Y, Jim MH, Yip GW-K, et al. Long term survival and prevalence of cardiac allograft vasculopathy in Chinese adults after heart transplantation: a retrospective study in Hong Kong. Int J Cardiol. 2016;220:787–8.

Article  PubMed  Google Scholar 

Awad MA, Shah A, Griffith BP. Current status and outcomes in heart transplantation: a narrative review. Rev Cardiovasc Med. 2022;23:1.

Article  Google Scholar 

Galeone A, Kirsch M, Barreda E, et al. Clinical outcome and quality of life of patients surviving 20 years or longer after heart transplantation. Transpl Int. 2014;27:576–82.

Article  PubMed  Google Scholar 

Hsu R-B, Chen RJ, Chou N-K, et al. Low incidence of malignancy after transplantation in Chinese heart allograft recipients. Transpl Int. 2005;18:283–8.

Article  PubMed  Google Scholar 

Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford University PressOxford; 2006.

Book  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

Article  PubMed  Google Scholar 

Pei L, Li R, Zhou H, et al. A physiologically based pharmacokinetic approach to recommend an individual dose of tacrolimus in adult heart transplant recipients. Pharmaceutics. 2023;15:2580.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen W, Zhang L, Zhang Y, et al. Expert consensus on individual treatment of tacrolimus for solid organ transplantation. Electr J Pract Organ Transpl. 2022;10:301–8.

Google Scholar 

Jing QM, Wang R, Chen X. Clinical analysis of 36 cases of allogeneic in situ heart transplantation. Chin Clin J Thorac Cardiovasc Surg. 2019;26:968–72.

Google Scholar 

Jiangsu Medical Security Bureau Jiangsu Provincial Medical Security Bureau Jiangsu Provincial Health and Health Commission on the announcement of the "Jiangsu medical service price item catalog (2022 version)" (Su Health insurance Fa (2023) No. 41). https://ybj.jiangsu.gov.cn/art/2023/7/27/art_85482_10965175.html. Accessed 16 Jan 2024.

Shiyong W. China health statistical yearbook 2022. 1st ed. Beijing: Peking Union College Press; (2022).

Zheng S, Zheng Z, Song Y, et al. Graft vascular disease after heart transplantation: a summary of long-term follow-up results in a single center in Fuwai Hospital. Organ Transpl. 2022;13:206–12.

Google Scholar 

Li Y, Zhang H, Meng X. Complications after heart transplantation and research status. Electr J Pract Organ Transpl. 2017;5:389–97.

Google Scholar 

Liu J-Y, You R-X, Guo M, et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation. Am J Ther. 2016;23:e810-824.

Article  PubMed  Google Scholar 

Jin C, Li W, Qiao S-B, et al. Costs and benefits associated with transradial versus transfemoral percutaneous coronary intervention in China. J Am Heart Assoc. 2016;5:e002684.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Lin Z, Yin H, et al. Clopidogrel versus aspirin for the treatment of acute coronary syndrome after a 12-month dual antiplatelet therapy: a cost-effectiveness analysis from China payer’s perspective. Clin Ther. 2018;40:2125–37.

Article  PubMed  CAS  Google Scholar 

Hong Z, Zhuang Y, Lu J, et al. Economic evaluation of three dialysis methods in patients with end-stage renal disease in China. Int Urol Nephrol. 2023;55:1247–54.

Article  PubMed  Google Scholar 

Huang M, Tian Y, He M, et al. Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. J Comp Eff Res. 2020;9:93–102.

Article  PubMed  Google Scholar 

Kang Yi. China statistical yearbook 2023. 1st ed. Beijing: China Statistics Press; (2023).

Clarke A, Pulikottil-Jacob R, Connock M, et al. Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program. Int J Cardiol. 2014;171:338–45.

Article  PubMed  Google Scholar 

Tadmouri A, Blomkvist J, Landais C, et al. Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database: Economic evaluation of LVAD in France. ESC Heart Fail. 2018;5:75–86.

Article  PubMed  Google Scholar 

Radeva JI, Reed SD, Kaló Z, et al. Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. Clin Transpl. 2005;19:122–9.

Article  Google Scholar 

Annemans L, Lemkuhl H, Tenderich G, et al. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation. Transpl Proc. 2007;39:3306–12.

Article  CAS  Google Scholar 

Gude E, Gullestad L, Andreassen AK. Everolimus immunosuppression for renal protection, reduction of allograft vasculopathy and prevention of allograft rejection in de-novo heart transplant recipients: could we have it all? Curr Opin Organ Transpl. 2017;22:198–206.

Article  CAS  Google Scholar 

Wang Y-J, Chi N-H, Chou N-K, et al. Malignancy after heart transplantation under everolimus versus mycophenolate mofetil immunosuppression. Transpl Proc. 2016;48:969–73.